Podcasts about Ovarian cancer

In this episode, we review the high-yield topic of ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ovarian Cancer⁠⁠⁠⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Featuring perspectives from Dr Deborah K Armstrong and Dr David M O'Malley, including the following topics: Introduction (0:00) PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37) Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O'Malley (35:18) CME information and select publications

Most of the menopause conversation happening right now, on social media, in podcasts, in the press, is aimed at women going through a natural hormonal transition. But there is a population of women whose menopause arrived differently. Suddenly and surgically. In the middle of one of the most frightening experiences of their lives, a cancer diagnosis or a high-risk prevention decision. This episode is for those women. And for every woman who loves one of them. My mother was 50 years old, on hormone therapy, when her breast cancer was diagnosed. Nobody talked about menopause then, what her future would look like, how the diagnosis would affect her long-term health, or what her options were. It wasn't until I was in my mid-forties, two decades later, that my own doctor finally brought up perimenopause. My guest, Elana Silber, CEO of Sharsheret, a national nonprofit supporting women, men, and families facing breast and ovarian cancer. Elana has spent her career at the intersection of cancer, women's health, and community, and she brings both professional expertise and deep personal commitment to one of the most underreported conversations in the menopause space: what happens when cancer forces the conversation. In this episode, we cover: The difference between natural menopause and surgically or chemically induced menopause after cancer treatment What breast and ovarian cancer diagnosis means for a woman's hormonal health, immediately and long-term Navigating survivorship and menopause simultaneously, the symptoms, the decisions, and the silence around both Hereditary cancer risk and what women need to know before menopause arrives How Sharsheret supports women and families through diagnosis, treatment, and survivorship If this episode resonates with you, share it with the women in your life navigating cancer, survivorship, or a hereditary risk decision. This is a conversation that needs to reach further than it currently does. Medical Disclaimer: This podcast is for informational purposes only and does not constitute medical advice. Do not use this content to diagnose or treat any medical condition. Consult your physician for any medical concerns. This disclaimer applies to all guests featured on this podcast. Learn more about Sharsheret: Website: www.sharsheret.org IG: @sharsheretofficial Stay connected with JFW: Book your 60-minute Menopause Care Consultation: https://www.jillfooswellness.com/menopause-care-consult-page Follow on Instagram: @jillfooswellness Follow on Facebook: @jillfooswellness Follow on YouTube: @jillfooswellness Grab discounts on my favorite menopause wellness products: https://www.jillfooswellness.com/health-products Enjoy 20% savings and free shipping at Fullscript for your favorite supplements by leading brands: https://us.fullscript.com/welcome/jillfooswellness/store-start Subscribe to the JFW newsletter at www.jillfooswellness.com and receive your FREE Guide on How To Create Your Menopause Health Equation Ebook. Schedule your free 15-minute consultation here: https://calendly.com/jillfooswellness/15-minute-zoom-consultations If you're a Chicago-area midlife woman, check out the Chicago Menopause Collective, a nonprofit dedicated to navigating menopause locally with experts: https://chicagomenopausecollective.org

Today, we're speaking to Dr Garth Funston, a GP and Clinical Senior Lecturer in Primary Care Cancer Research at Queen Mary University of London. Title of paper: Using large language models to identify pre-diagnostic clinical features of ovarian cancer from healthcare records: a population-based case-control studyAvailable at: https://doi.org/10.3399/BJGP.2025.0366Most women with ovarian cancer present with symptoms, but many symptoms are recorded only in free text healthcare records and missed by studies and clinical decision support tools that rely on coded data. We found that using large language models (LLMs) to extract symptoms from free text records substantially increased symptom detection and strengthened associations with ovarian cancer. Incorporating LLM-extracted symptom information into research and clinical decision tools may support identification of women at higher risk of cancer and aid appropriate investigation.TranscriptThis transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.Speaker A00:00:00.800 - 00:00:50.940Hi and welcome to BJGP Interviews. I'm Nada Khan and I'm one of the Associate editors of the Journal. Thanks for listening to this podcast today.In today's episode, we're talking to Dr. Garth Funston, who is an academic GP and clinical senior Lecturer in Primary Care Research at Queen Mary University of London.We're here to talk about his recent paper in the BJDP which is titled Using Large Language Models to Identify Pre Diagnostic Clinical Features of Ovarian and Cancer from Healthcare Records.So, Garth, thanks so much for talking to us again today, but I wonder, just before we get into the AI side of this paper, can you briefly explain the clinical problem you're trying to address here with ovarian cancer diagnosis in general practice?Speaker B00:00:51.500 - 00:01:55.010So most women with ovarian cancer are diagnosed after they develop symptoms and see their doctor. The challenge is that most symptoms are really non specific. There's no real red flag symptoms for ovarian cancer.That makes it a real clinical challenge for the GP to kind of recognize it and perform tests.So the symptoms are things like abdominal and pelvic pain, persistent bloating, urinary urgency and frequency, things that we see really frequently in gp. So knowing when to consider ovarian cancer is the big challenge.And we know that certainly a proportion of women see their GP multiple times before the diagnosis. Now we're lucky for ovarian cancer in that we have reasonably good triage tests and CA125 and transvaginal ultrasound.So the challenge really is to identify women with these non specific symptoms early so as we can work out who to test and hopefully improve early diagnosis and on outcomes in that way.Speaker A00:01:55.250 - 00:02:14.530Yeah, and I'm sure you're well aware of sort of the body work around this area and people like Willie Hamilton, who's done work around early diagnosis of ovarian cancer, along with Claire Bankhead, and they did some really interesting work around things like bloating, didn't they? But that was slightly different, I think, and a little bit that's some time ago now, isn't it?Speaker B00:02:14.930 - 00:02:39.230Yeah, it was some time ago. I think all of that is, you know, fundamental and still holds true.And they did a lot of work around things like IBS and in women over, over 50 and things like that that are kind of these subtle signs that we need to be aware of with ovarian cancer.So, yeah, we know there's lots of features that are associated with ovarian cancer, but it's recognizing when to invest to get those features because they're so common.Speaker A00:02:39.630 - 00:02:49.310Yeah. And do you think that's why it's described as difficult to diagnose early in general practice? Is it because the symptoms are so common?What are your thoughts on that?Speaker B00:02:49.390 - 00:03:48.750I think there's a few reasons.I think ovarian cancer used to be called, certainly in the media, the kind of the silent killer and terminology, which I really, really frustrates me, because we know it's not. We know that most women of symptoms for diagnosis. We actually know that from this paper and other papers that are symptoms in early stage cancer.But that kind of thought around ovarian cancer still holds. Secondly, the symptoms are nonspecific, they're reasonably common. I mean, you know, I probably see a.A patient with abdominal pain most days and it's kind of working out which ones to investigate for ovarian cancer. Yeah. And so I think those are the main things. And thirdly, it's, you know, it's not the most common common cancer.GP will see people probably only encounter a case of ovarian cancer every three to five years, a new case. And that's the extra challenge. It's kind of suspecting it when it's a rare thing in primary care.Speaker A00:03:49.100 - 00:04:03.500Yeah. And one thing I found really interesting about this work is that you're using free text clinical records rather than just coded data.So can you tell us a little bit about the data you accessed here and why it was so important to use this free text data?Speaker B00:04:04.220 - 00:05:09.600So a lot of the work that we do with primary care data focuses on coded data and certainly within the uk, because that's really the data we can actually access within UK for research purposes. But up to 80% of clinical information is not in that coded format, it's in the free text.And work from people like Sarah Price in the past have shown that often subtle things that we need to pick up are in the free text and GPS don't code that.So it's something I've been really keen to use in research for many years now to try and look at what extra information is there in the free text that could help us in both research and clinical practice and kind of picking up these cancers. And the data we accessed was from the United States, it was from healthcare clinics associated with the University of Washington.And that included kind of coded data, but also the free text medical records of patients which had been anonymized and were accessed in a kind of a safe and appropriate way.Speaker A00:05:10.000 - 00:05:40.140Yeah.And I think a lot of clinical staff listening to this will certainly, certainly appreciate that a Lot goes into the notes that we just type in that doesn't really get coded. So it's phenomenal that you're able to access that data.And this paper uses large language models or LLMs, which some people might associate, associate with tools like ChatGPT, but just at a very basic level. Can you just talk us through what actually is a large language model and what sort of it was used for in this, in this study?Speaker B00:05:40.950 - 00:06:49.130Large language models, lots of people use them on a daily basis. Absolutely right.Things like ChatGPT, they're essentially a tool for our purposes which we use to extract information from the free text medical records. Now natural language processing approaches have been used actually for many years, kind of rule based approaches.Other models, these require lots of training. You need to lots of highly annotated records and notes to train the models.Advantage of large language models, things like GPT, is they need less annotated notes and we did still do some of that, but they require less and that makes them much easier to apply and use in practice. We use them in this setting to effectively pull out key information on symptoms.We predefined a list of 17 symptoms from the literature which were associated with ovarian cancer and we used the large language models to go through the notes, pull out information on those symptoms that we could use in the study alongside the coded data.Speaker A00:06:50.090 - 00:07:03.350And I think that as we've been discussing, these large language models are probably really useful for this kind of data. I think especially because a lot of general practice is narrative and contextual as we've been discussing as well.Speaker B00:07:03.350 - 00:07:38.940Yeah, I think, I mean there's two challenges with using free text data. One is access requirements because there's lots of concerns around confidentiality. The other is just the volume of it.You've got these massive records that you know, contain lots of information, lots of writing, go back years. How do you actually process that to find the key information that you need?I think large language models are a really useful tool here because with a bit of training you can use them to actually extract the information that's pertinent to your kind of question.Speaker A00:07:39.340 - 00:07:48.620So let's go into what you found and I'm really interested to know about what kind of patterns or features was this model able to identify before an ovarian cancer diagnosis.Speaker B00:07:49.180 - 00:09:06.690So we looked at 17, 17 features. We find actually that 14 of the features were more frequently recorded within the free text and coded...

In this episode, we hear about a breakthrough drug called mirvetuximab, which has been dubbed a "biological missile" in the treatment of ovarian cancer. Plus, astronomers suggest some black holes may have formed before the stars in their host galaxies; a 'killer fungus' that could help habitats damaged by invasive moss; and Blue Origin officials assess the damage caused by the New Glenn rocket's dramatic explosion in Florida. Like this podcast? Please help us by supporting the Naked Scientists

Survivors who say they were abused by former Harrods owner Mohamed Al Fayed met Sir Keir Starmer yesterday afternoon, in what campaigners have described as a potentially significant moment. More than 400 allegations of sexual misconduct against Al Fayed, dating back to 1977, have now been made. The meeting was organised by The Survivors Trust and the All-Party Parliamentary Group on the Survivors of Mohamed Al Fayed and Harrods. Kylie Pentelow was joined by Lucy Duckworth from The Survivors Trust and survivor Carrie Lazell.A breakthrough drug for ovarian cancer that is kinder on the body and extends lives is now available on the NHS. Victoria Clare from Ovacome and patient Patricia Hill talk to Kylie. New Ground is the UK's first purpose-built co-housing community for women over 50, designed and developed on their own terms. Each resident has her own self-contained flat, along with shared spaces. The women moved in 10 years ago, and the community is still going strong. But what's it really like to live this way? And could co-housing be a model more women should consider? Kylie speaks to two residents, Jude and Ann.Stories about queens and princesses have shaped some of our most enduring ideas about womanhood. Historian Kate Williams joins Kylie to discuss her new book, Regina: A New History of Women and Power, which spans thousands of years, from the queens of ancient Egypt to the modern day.Presenter: Kylie Pentelow Producer: Corinna Jones

In recognition of Endometrial Cancer Awareness Month, this episode features Jennifer Graham, a three-time cancer patient and patient advocate with the Marathon of Hope Cancer Centres Network (MOHCCN). Jennifer shares her experiences navigating breast, endometrial, and ovarian cancer, reflecting on the emotional realities of diagnosis, treatment, survivorship, and living with uncertainty. Together, we discuss the importance of support systems, how cancer shaped her perspective on life and advocacy, and the role of patient voices in improving cancer research and care. Through her story, Jennifer offers an honest and hopeful conversation about resilience, community, and moving forward through even the most difficult moments.For more information on the Gynecologic Cancer Initiative, please visit https://gynecancerinitiative.ca/ or email us at info@gynecancerinitiative.ca  Where to learn more about us:  Twitter – @GCI_Cluster Instagram – @gynecancerinitiative Facebook – facebook.com/gynecancerinitiativeTikTok – @gci_gosh

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

Dr. Marty Makary out as FDA Commissioner—was he the victim of a BigPharma purge? Are “liquid biopsies” useful for predicting recurrences, as well as guiding therapy, for cancer? Nighttime smartphone by adolescents surges, eroding kids' sleep needs; Persistent itch may require an “all of the above” approach to break its vicious cycle—could topical vitamin B12 provide an answer? Study critiques research methods that fast-tracked new Alzheimer's drugs.

There's a surgery to remove the fallopian tubes as a permanent method of birth control that could also reduce a woman's risk of the most common ovarian cancer. But a group of B.C. researchers and physicians say the procedure isn't widely known across Canada. They're trying to change that.

Proceedings from a live event on April 12, 2026, held during the SGO 2026 Annual Meeting on Women's Cancer and moderated by Dr Shannon Westin, including the following topics: Introduction (0:00) Current Role of PARP Inhibitors for Advanced Ovarian Cancer — Prof Colombo (1:59) Strategies Targeting Folate Receptor Alpha for Advanced Ovarian Cancer — Dr Westin (25:53) Other Novel Agents and Strategies for Advanced Ovarian Cancer — Dr Olawaiye (46:40) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced Ovarian Cancer — Dr Konecny (1:19:11) CME information and select publications

Today, we're taking a flavorful journey to Jamaica through food, culture, and storytelling. Joining us is celebrated chef, three-time Chopped champion, and culinary ambassador Chef Andre Fowles, whose new cookbook, My Jamaican Table: Vibrant Recipes from a Sun-Drenched Island, shares more than 100 recipes inspired by the warmth, resilience, and rich traditions of Jamaica. From authentic jerk cooking and curry goat to modern Caribbean-inspired creations, Chef Fowles discusses how food reflects history, culture, and community — and why preserving culinary traditions matters. We also talk about his inspiring journey from Kingston to becoming one of the most recognized Jamaican chefs in the world, along with his commitment to giving back through community and recovery efforts in Jamaica. My Jamaican Table: Vibrant Recipes from a Sun-Drenched Island was published by Artisan Books on March 10, 2026. Learn more:• My Jamaican Table by Andre Fowles Follow on social media:• Instagram: @cheffowles World Ovarian Cancer Day & OCRA May 8 marked World Ovarian Cancer Day, a global effort to raise awareness about one of the most difficult cancers to detect early. Today, we're joined by Audra Moran, President and CEO of the Ovarian Cancer Research Alliance, the world's largest organization dedicated to advancing ovarian and gynecologic cancer research while supporting patients and caregivers through education, advocacy, and critical resources. We discuss the warning signs and risk factors associated with ovarian cancer, the importance of understanding family history and genetic testing, and how women can advocate for their health in medical settings. Audra also shares details about OCRA's groundbreaking Community Accelerated Research Exchange and “Living Lab,” an innovative initiative designed to transform how patient experiences inform cancer research in real time.Learn more:• Ovarian Cancer Research Alliance (OCRA) Follow on social media:• Instagram: OCRA Instagram• X/Twitter: OCRA X/Twitter

Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Listen to the podcast here

Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Download the transcript here

  The Honorable Tina Brozman Foundation for Ovarian Cancer Research (Tina's Wish) is a nonprofit organization dedicated to funding innovative scientific research for the prevention and early detection of ovarian cancer and to providing gynecologic health education. Know Early. Know Hope.® This is their mission. On this episode I'm joined by Beverly Wolfer, Executive Director and Joyce Kulhawick, 3 time cancer survivor. Since its inception, the foundation has raised over $29 million for its cause. Annually, Tina's Wish now funds $2.4 million of scientific research for the early detection and prevention of ovarian cancer. The ladies share information on the organizations mission, the research their doing along with signs/symptoms and the importance of self advocacy. Ovarian Cancer Non Profit Organization and Awareness

Dr. Prather says that "100% of women" need help in balancing their hormones based on the lab tests he sees in patients.  In this episode, you'll learn:—How women have 64 different Hormones to consider when trying to balance them, while men basically have to worry about 2.  And why Dr. Prather says that balancing a woman's hormones is like trying to target "a jackrabbit jumping all over the place".—Why Dr. Prather says that every woman should think about being on some sort of supplementation to help balance her hormones.—The symptoms of hormonal imbalance, including: hot flashes, mood changes, cramps, irregular periods, immune system issues, heart palpitations, and even digestion problems. —The risks of pharmaceutical hormones, which only 2% of women should actually be taking according to research.  And why bioidentical hormones are NOT natural, even though some women taking them think they are.—The role of "food grade" Herbals, Glandulars, and Homeopathics in helping the body to regulate your hormones naturally and without the risk of side effects.  And how Holistic Integration can actually test to see which ones will work best for you.—Why Dr. Prather says that you are not going to balance the hormones if your Copper/Zinc ratio is not balanced.  And how Breast Cancer and Ovarian Cancer "increase quite dramatically" when a woman has too high Copper levels.—How balancing your hormones can often balance your Cholesterol.  And how getting your Cholesterol too low (under 140) will interfere with the balance of your hormones. —Why Iodine "is absolutely critical for females."  And how women who take Thyroid medication have "a very large jump in your chances of having Breast Cancer" and low Iodine is "the leading cause of Breast Cancer".—Why Dr. Prather says that, if your Liver is not working right, "you will never get your Hormones completely balanced".  And how the Adrenals can make every single hormone in the body, but are low-functioning in almost everyone.—The Diagnostics you should have to diagnose the state of your Hormone Health.  And why Chiropractic & Acupuncture are important for balancing out your Hormones and causing "almost immediate" changes.http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O'Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical CollegeYvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British ColumbiaChristina Washington, MD; Stephenson Cancer Center, University of OklahomaUrsula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O'Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Ovarian cancer is often referred to as a ‘silent' cancer, because its symptoms can be vague and easily mistaken for everyday issues. In Ireland, hundreds of women are diagnosed each year, often at a later stage…Joining Andrea to share her experience is listener Dee Flannelly, as well as Dr Claire Thompson, a Consultant Gynaecological Oncologist in the Mater Misericordiae University Hospital and Rotunda Hospital in Dublin.

Community News and Interviews for the Catskills & Northeast Pennsylvania

What does prevention really look like when cancer risk is part of your life? In this episode of The SEAM Podcast, Amy Cohen Epstein sits down with Dr. Mona Guo, gynecologic oncologist at USC Keck and part of the Lynne Cohen Foundation Preventive Care Clinic, for a conversation on risk-reducing surgery, ovarian cancer treatment, and the deeply personal decisions women face in navigating care. Drawing on her work with women at increased risk for breast and ovarian cancers, Dr. Guo offers a clear-eyed perspective on fallopian tube removal, hormonal prevention strategies, menopause, self-advocacy, and quality of life during and after treatment.For more, follow The Seam on Instagram, watch full episodes on Youtube, or visit the Lynne Cohen Foundation website.Produced by Peoples Media Hosted on Acast. See acast.com/privacy for more information.

Send us Fan MailMorning Prayer (Trust God - Love Others; Ovarian Cancer; Law Enforcement / Military; Humility Before God & People; Resist Devil)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/CKF865. CME/CPE/IPCE credit will be available until April 26, 2027.Putting Pharmacist-Led Solutions Into Practice for Endometrial and Ovarian Cancer Care: Integrating Modern Therapies Into Personalized Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AstraZeneca, GSK, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/CKF865. CME/CPE/IPCE credit will be available until April 26, 2027.Putting Pharmacist-Led Solutions Into Practice for Endometrial and Ovarian Cancer Care: Integrating Modern Therapies Into Personalized Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AstraZeneca, GSK, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/CKF865. CME/CPE/IPCE credit will be available until April 26, 2027.Putting Pharmacist-Led Solutions Into Practice for Endometrial and Ovarian Cancer Care: Integrating Modern Therapies Into Personalized Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AstraZeneca, GSK, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/CKF865. CME/CPE/IPCE credit will be available until April 26, 2027.Putting Pharmacist-Led Solutions Into Practice for Endometrial and Ovarian Cancer Care: Integrating Modern Therapies Into Personalized Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AstraZeneca, GSK, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/CKF865. CME/CPE/IPCE credit will be available until April 26, 2027.Putting Pharmacist-Led Solutions Into Practice for Endometrial and Ovarian Cancer Care: Integrating Modern Therapies Into Personalized Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AstraZeneca, GSK, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/CKF865. CME/CPE/IPCE credit will be available until April 26, 2027.Putting Pharmacist-Led Solutions Into Practice for Endometrial and Ovarian Cancer Care: Integrating Modern Therapies Into Personalized Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AstraZeneca, GSK, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Send us Fan MailMorning Prayer (2nd Greatest Commandment; Ovarian Cancer; Teachers & Education; Know You By Your Love)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

Joining Pat to discuss some promising advances in treating pancreatic & ovarian cancer is Dr Luke O'Neill.

Editor's Choice:  Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancerEditorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selectionHosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta CanadaFeaturing: Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAAlexander Melamed, MD MPH, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USAJose Alejandro Rauh-Hain, MD MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Melissa and Mandy are reunited (and it feels so good) to discuss Breaking News regarding Tiger Woods, Southern Charm and Summer House. Mandy starts by providing some personal updates. Mandy shares theories on why Madison changed her BravoCon tune with Craig. They also discuss Craig vs. Venita and Craig's personality characteristics.M&M discuss Kyle's king baby tantrum and the Amanda & West rumors. Mental Health and addiction are discussed throughout.THANK YOU FOR LISTENING and for all the support! Please follow YBT podcast and give a 5-star comment & rating (it really helps!) Please follow @yourbishtherapist on Instagram, Patreon, YouTube, FB, and TT For full video (ad free, bonus content & early releases) visit YBT Patreon, Spreaker Supporters Club or YouTube Patreon: https://patreon.com/YourBishTherapist?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLinkAPPLE PODCAST https://apple.co/3MfskzeSpreaker Supporters club:  https://www.spreaker.com/podcast/your-bish-therapist--6065109/support YouTube: https://www.youtube.com/channel/UCu8bmVPTlWANg5v7rGRJjow?subconfirmation=1To find links to all YBT content: https://linktr.ee/yourbishtherapistBrand Ambassador: www.Iamhumanthebrand.com for clothing with a purpose. Code BISH20 for 20% off purchaseDisclaimer: Posts are not intended to diagnose, treat or provide medical advice. Your Bish Therapist (YBT) is for entertainment and informational purposes only. The podcast, my opinions, and posts, are my own and are not associated with past or present employers, any organizations, Bravo TV, Grey Heart productions or any other television network. The information in YBT podcast and on its its social media is provided for general informational purposes only and is not intended to diagnose or treat. Please do not act or refrain from acting based on anything you read, see, or hear on YBT, podcast or associated social media. Communicating with YBT via email, and/or social media does not form a therapeutic alliance. Melissa, operator of YBT, is unable to provide any therapeutic advice, treatment or feedback.

In this profoundly moving and eye-opening episode, Dr. Fiona Lovely welcomes back Dr. Tammy O'Rourke, a Nurse Practitioner with a PhD and a leading voice in hormone health. While their last conversation focused on advocating for patients, this time, Dr. O'Rourke shares a harrowing personal health journey that began with symptoms easily dismissed as menopausal—bloating, fatigue, and reflux. What followed was a terrifying navigation of a healthcare system that seemed designed to fail her, despite her own expertise. Dr. O'Rourke details the delays, the dismissals, and the bureaucratic barriers that turned a treatable condition into a stage 3C ovarian cancer diagnosis. Listeners will hear how her intuition, combined with the unwavering advocacy of her husband, led her to seek care in the United States for a specialized CRS HIPEC surgery—a life-saving procedure not readily accessible in Canada. This episode is a powerful testament to the importance of self-advocacy, highlighting the specific risks for women with a history of endometriosis and fibroids. Dr. O'Rourke emphasizes the critical need for women to never give up control of their hormone health, to trust their gut, and to pursue second opinions, even when the system pushes back. It's a story of survival, systemic failure, and the urgent call for better care for all women. In this episode, they talk about: The shocking reality of navigating a universal healthcare system during a cancer crisis How endometriosis and fibroids significantly increase the risk of ovarian cancer The crucial role of the CA-125 blood test and pelvic ultrasound in early detection The life-saving potential of CRS HIPEC surgery and why it's not widely available in Canada Tune in to hear how one of the country's leading hormone experts had to fight for her own life, and learn the steps you can take to ensure you don't get left behind. To listen to my first interview with Tammy, listen here. If you want to know more about Tammy, find her here: Website | Instagram | Linkedin | YouTube | Facebook Thank you to our sponsors for this episode:

Can the right exercise really 'age-proof' your body? Could you really lower your risk of ovarian cancer by asking your surgeon to remove your fallopian tubes while they’re already performing another routine procedure? And what do you do when decades of dieting have left you with what feels like weight-loss PTSD? In this episode, we talk to Professor Jeff Coombes from the University of Queensland to find out why 'high-intensity' doesn't have to be terrifying and which specific exercise actually drops your risk of heart disease and diabetes. We also talk about why the fallopian tubes - not the ovaries - might be the true starting point for some ovarian cancers and how 'opportunistic' surgery could save lives. Plus, in our Quick Consult, Dr Mariam helps Carolyn, who is 40 and struggling with the mental and physical burnout of PCOS and weight-loss plateaus. We explain why ‘calories in, calories out’ is a toxic myth and how to rebuild trust with a body you feel has betrayed you. EPISODE RESOURCES If this episode has raised concerns for you regarding body image, eating disorders, or chronic illness support, the following resources are available: Butterfly Foundation: Support for eating disorders and body image issues. Call 1800 33 4673. Jean Hailes for Women's Health: A leading resource for PCOS, hormones and women’s health. Diabetes Australia: Information on pre-diabetes management and support. Lifeline: If you are feeling overwhelmed and need someone to talk to, please call 13 11 14. And, if you want to learn more about the topics discussed in today’s show, check out these helpful links: MOVE by Mamamia Health Direct - Physical Activity Guidelines GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Hosts: Claire Murphy and Dr Mariam Guest: Professor Jeff Coombes Senior Producers: Claire Murphy and Sally Best Group Executive Producer: Ilaria Brophy Audio Producer: Scott Stronach Video Producer: Julian Rosario Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYK865. CME/CC/AAPA credit will be available until March 12, 2027.Pathway to Precision in Ovarian Cancer: A Pathology-Informed Guide to Translating Biomarker Testing Results Into Actionable Treatment With ADCs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Dr. Refky Nicola speaks with Dr. Atul Shinagare about his team's research showing that incidental adnexal lesions on single‑phase CT are often difficult for radiologists to classify consistently, with only certain classic lesions yielding strong agreement. Their conversation underscores the limitations of CT compared with ultrasound or MRI and reinforces that most incidental adnexal findings are benign, though many still require additional imaging for clarification. Imaging in Advanced Epithelial Ovarian Cancer: Assessment of Peritoneal Spread. Nougaret and Lakhman et al. Radiology 2026; 318(3):e250116.

In this deeply personal episode Jin Ong sits with Jess — a health, life and mindset coach — to trace her journey from long-term emotional work and a hysterectomy through an unexpected ovarian cancer diagnosis, surgery, chemotherapy, and powerful breakthroughs in self-love, creativity and life direction. Jess shares how the Release work helped her process trauma and physical symptoms, how intuition and community supported her treatment choices, and how she reclaimed creativity and vision through the hardest 18 months of her life. A brave, honest conversation about falling apart and putting yourself back together — physically, emotionally and creatively. If Jess's story resonates, listen in, and consider the small consistent practices that support both healing and the life you want to create. Episode Highlights: - Emotional processing can reduce physical symptoms and support recovery: Jess' nausea and other symptoms reduced after doing the Release work. - Integrating intuition, medical guidance and complementary support (naturopathy, nutrition, mindset) helped Jess make treatment decisions that felt aligned to her. - Group space and coached emotional tools (quick releases, written dumps, boundary work) provided practical coping strategies during medical uncertainty and chemo. - Trauma, grief and big life change can catalyse clarity: through this challenge Jess clarified values, deepened self-love, and reclaimed creative purpose. - Desire statements, small rituals, and embodied gratitude supported resilience and practical outcomes (including business transitions and personal goals). Who this episode is for: - Anyone navigating chronic health issues, major surgery, or cancer treatment. - Coaches, healers, and helpers who want to see how to receive support while supporting others. - Listeners curious about the intersection of emotional work, intuitive decision-making, and conventional medical care. - People considering structured emotional-processing programs like Release. Links & Next Steps: Join the Release waitlist & learn about the new way to enter the Release world: https://theartoflisteningtoyourbody.com/release-course *Integration support is now included before live rounds begin If you have questions about Release or whether it's right for you, you can reach out to Jin via social media The video as mentioned on Endometriosis: https://theartoflisteningtoyourbody.com/endometriosis  Connect with Jess: @jess.eastwood.coaching on insta. Website is www.jesseastwood.com

Featuring perspectives from Prof Nicoletta Colombo and Dr Kathleen N Moore, including the following topics: Introduction (0:00) Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer (2:35) Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer(41:48) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 1: Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer — Angeles Alvarez Secord, MD, MHSc CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Ovarian Cancer | Faculty Presentation 2: Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer — Nicoletta Colombo, MD CME information and select publications

In this episode of Plugged Into Public Health, Lauren speaks with Dr. Jill Kolesar about ovarian cancer, precision medicine, and the challenges of translating scientific discovery into real-world care. Dr. Kolesar explains why ovarian cancer remains difficult to treat, including late-stage diagnosis and limited response to immunotherapy. She shares her team's work on a novel cell-based therapy designed to convert “cold” tumors into ones the immune system can attack, with the goal of improving effectiveness while reducing toxicity. The conversation also explores molecular tumor boards, the role of pharmacists in precision oncology, and how collaboration and data sharing help bring innovation to community and rural settings. This episode highlights not only cutting-edge science, but the systems required to ensure that breakthroughs actually reach patients. A transcript of this episode will be available here soon. Have a question for our podcast crew or an idea for an episode? You can email them at CPH-GradAmbassador@uiowa.edu You can also support Plugged in to Public Health by sharing this episode and others with your friends, colleagues, and social networks. #publichealth #cancer #cancercare #ovariancancer #precisionmedicine #immunotherapy #healthcare #pharmacology #medicaltechnology #iowacity

In this conversation, Sabrina Stanley reflects on returning to competition after being diagnosed with ovarian cancer at the peak of her ultrarunning career. She recounts the medical uncertainty that followed her initial diagnosis, the surgeries, chemotherapy, and ongoing immunotherapy that reshaped more than a year of her life. Stanley discusses racing again while still in recovery, including her recent return at the Arc of Attrition 100, and what it meant to simply reach the start line.She also speaks candidly about her complicated relationship with the sport itself -why she doesn't closely follow ultrarunning, how she intentionally limits her exposure to public opinion, and how she has built a professional career largely insulated from external narratives. The conversation touches on her partnership with OnlyFans, her views on athlete autonomy and body regulation, and the tradeoffs of stepping outside traditional sponsorship models while continuing to pursue elite performance.Timestamps:00:00 Sabrina's Unique Perspective on Ultra Running06:14 The Misunderstood World of OnlyFans12:03 The Impact of Ovarian Cancer on Sabrina's Career24:30 Navigating Cancer and Social Connections27:55 Training Through Treatment: A Personal Journey39:01 The Ongoing Battle: Living with Uncertainty44:56 Racing Again, Arc of Attrition 100 MilerPartners:Raide - Making equipment for efficient human-powered movement in the mountains (https://raideresearch.com/singletrack)Precision Fuel and Hydration - use code SINGLETRACK at checkout for 15% off your next order (https://www.precisionhydration.com/planner/?utm_source=partner&utm_medium=podcast&utm_campaign=singletrack)Norda - check out the 005: the lightest, fastest, most stable trail racing shoe ever made (https://nordarun.com/)Janji - premium trail running apparel (https://janji.com/)Support the show

Ovarian cancer may be prevented with removal of the fallopian tubes during pelvic or select abdominal surgery in eligible women. This procedure, opportunistic salpingectomy, can be offered to more eligible women. Author Jurgen M. Piek, MD, PhD, of the Catharina Cancer Institute discusses this and more with JAMA Deputy Editor Linda Brubaker, MD, MS. Related Content: Opportunistic Salpingectomy for Prevention of Tubo-Ovarian Carcinoma

Today, we’re bringing you the best from the KUOW Newsroom… The City of Seattle is putting a stronger emphasis on SERVICES for people arrested for public drug use. Researchers are trying a new approach to treating ovarian cancer, often called “the silent killer.” And a primer ahead of tomorrow’s huge NFC Championship game, where the Seattle Seahawks face off against the Los Angeles Rams. We can only make Seattle Now because listeners support us. Tap here to make a gift and keep Seattle Now in your feed. Got questions about local news or story ideas to share? We want to hear from you! Email us at seattlenow@kuow.org, leave us a voicemail at (206) 616-6746 or leave us feedback online.See omnystudio.com/listener for privacy information.

In this episode of The Jordan Syatt Podcast, I speak with Elana Silber, The CEO of Sharsheret (@sharsheretofficial), a national non-profit organization that helps women and families living with breast and/or ovarian cancer.We discuss:- How Sharsheret fills the gaps in cancer support- Genetic testing and BRCA awareness- How you can get help from Sharsheret for free- How Sharsheret came to be- And more...I hope you enjoy this episode and, if you do, please leave a review on iTunes or Spotify (huge thank you to everyone who has written one so far).Finally, if you've been thinking about joining The Inner Circle but haven't yet... we have hundreds of home and bodyweight workouts for you and you can get them all here: https://www.sfinnercircle.com/